Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOOD-IDES-01: Imlifidase in Anti-GBM Disease
NCT03157037Phase 2Completed
- Sponsor
- Mårten Segelmark
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Therapeutic Enzymes
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in anti-glomerular basement membrane disease, sponsored by Mårten Segelmark. Primary endpoint: Number of Patients With Independent Renal Function at 6 months. Started Jun 2017; status: completed.
02
Drugs
imlifidase
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on NCT03157037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157037.